Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SUCNR1 | Q9BXA5 | 16/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223345 | 0.85 | SUCNR1 (0.46) | ALDH1A1SUCNR1PDE10AOXGR1 | |
| SCHEMBL6129289 | 0.81 | KCNH2 (0.55) | ALDH1A1SUCNR1PDE10AOXGR1 | |
| SCHEMBL20517681 | 0.80 | SUCNR1 (0.49) | SUCNR1PDE10AOXGR1KDM4EMEN1 | |
| SCHEMBL29955429 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SUCNR1PDE10AOXGR1KDM4E | |
| SCHEMBL30930276 | 0.78 | SUCNR1 (0.50) | SUCNR1PDE10AOXGR1 | |
| SCHEMBL24193793 | 0.78 | SUCNR1 (0.57) | SUCNR1OXGR1KDM4EMEN1LMNA | |
| SCHEMBL30471836 | 0.78 | SUCNR1 (0.57) | SUCNR1OXGR1KDM4EMEN1LMNA | |
| SCHEMBL276117 | 0.78 | SUCNR1 (0.50) | ALDH1A1SUCNR1PDE10AOXGR1KDM4E | |
| SCHEMBL6899530 | 0.78 | SUCNR1 (0.47) | ALDH1A1SUCNR1PDE10AOXGR1 | |
| SCHEMBL20140387 | 0.76 | PDE10A (0.45) | ALDH1A1SUCNR1PDE10AOXGR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| WO-2020146521-A2 | RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ALDH1A1 2970/4885SUCNR1 2824/4885PDE10A 4639/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | ALDH1A1 693/4885SUCNR1 564/4885PDE10A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.